Ventyx宣布对VTX 2735、VTX 3232进行第二阶段试验;肥胖数据预计将于2025年下半年发布，帕金森氏数据将于2025年上半年发布; 2.529亿美元资金将延长至2026年下半年

First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025

Phase 2 trial of VTX2735 in participants with recurrent pericarditis expected to initiate in January, with topline data expected in H2 2025

Topline data from ongoing Phase 2 biomarker trial of VTX3232 in participants with early Parkinson's disease expected in H1 2025

Cash, cash equivalents and marketable securities balance of $252.9M as of December 31, 2024 (unaudited) expected to fund operations into at least H2 2026

SAN DIEGO, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today highlighted its 2025 pipeline strategy and provided clinical updates on its NLRP3 inhibitor portfolio, including VTX2735 and VTX3232.